Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 17/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.79 |
| ▸ | SCN1A | P35498 | 2/20 | 0.79 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.79 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.79 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.79 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.79 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819014 | 0.88 | SCN10A (1.00) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL25567465 | 0.82 | SCN10A (0.84) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL15007948 | 0.77 | SCN10A (0.54) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL5949923 | 0.77 | SCN10A (0.54) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL12549011 | 0.76 | SCN10A (0.76) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL17066290 | 0.76 | SCN10A (0.53) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL1690431 | 0.75 | SCN2A (0.55) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL25303086 | 0.75 | SCN10A (0.71) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| Bromide SCHEMBL25435849 | 0.74 | SCN10A (0.70) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL26094793 | 0.74 | TRPV1 (0.68) | SCN10AKCNH2SCN1ASCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201170-A1 | ANALGESIC AND ANTIPRURITIC PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KEVICI (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201170-A1 | ANALGESIC AND ANTIPRURITIC PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SCN8A, SCN7A, SCN1A | SCN10A 8/4885KCNH2 77/4885SCN1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.